Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53
Abstract Acetylation is critically required for p53 activation, though it remains poorly understood how p53 acetylation is regulated in glioblastoma (GBM). This study reveals that p53 acetylation is a favorable prognostic marker for GBM, regardless of p53 status, and that Smad1, a key negative regul...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202402258 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582750706597888 |
|---|---|
| author | Lingli Gong Daxing Xu Kaixiang Ni Jie Li Wei Mao Bo Zhang Zhening Pu Xiangming Fang Ying Yin Li Ji Jingjing Wang Yaling Hu Jiao Meng Rui Zhang Jiantong Jiao Jian Zou |
| author_facet | Lingli Gong Daxing Xu Kaixiang Ni Jie Li Wei Mao Bo Zhang Zhening Pu Xiangming Fang Ying Yin Li Ji Jingjing Wang Yaling Hu Jiao Meng Rui Zhang Jiantong Jiao Jian Zou |
| author_sort | Lingli Gong |
| collection | DOAJ |
| description | Abstract Acetylation is critically required for p53 activation, though it remains poorly understood how p53 acetylation is regulated in glioblastoma (GBM). This study reveals that p53 acetylation is a favorable prognostic marker for GBM, regardless of p53 status, and that Smad1, a key negative regulator of p53 acetylation, is involved in this process. Smad1 forms a complex with p53 and p300, inhibiting p300's interaction with p53 and leading to reduced p53 acetylation and increased Smad1 acetylation in GBM. This results in enhanced tumor growth and resistance to chemotherapy, particularly in tumors with missense mutant p53. Acetylation of K373 is found to be essential for Smad1's oncogenic function but does not confer chemoresistance in the absence of p53. Through molecular docking, it is discovered that Smad1 and p53 both interact with the acetyltransferase domain of p300, but at different amino acid sites. Disturbing the interface of Smad1 through amino acid mutations abolishes the Smad1‐p300 complex and promotes p53 acetylation. Therefore, a small molecule is identified through virtual screening that specifically disrupts the Smad1‐p300 interaction, offering a promising strategy for inhibiting GBM and increasing chemosensitivity by inhibiting Smad1 acetylation and restoring p53 acetylation. |
| format | Article |
| id | doaj-art-67945b9a572f47a48bc06a214b332b47 |
| institution | Kabale University |
| issn | 2198-3844 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advanced Science |
| spelling | doaj-art-67945b9a572f47a48bc06a214b332b472025-01-29T09:50:19ZengWileyAdvanced Science2198-38442025-01-01124n/an/a10.1002/advs.202402258Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53Lingli Gong0Daxing Xu1Kaixiang Ni2Jie Li3Wei Mao4Bo Zhang5Zhening Pu6Xiangming Fang7Ying Yin8Li Ji9Jingjing Wang10Yaling Hu11Jiao Meng12Rui Zhang13Jiantong Jiao14Jian Zou15Department of Laboratory MedicineThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's HospitalWuxi Medical CenterNanjing Medical UniversityWuxi Jiangsu 214023 ChinaDepartment of Laboratory MedicineThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's HospitalWuxi Medical CenterNanjing Medical UniversityWuxi Jiangsu 214023 ChinaWuxi Medical CenterNanjing Medical UniversityWuxi Jiangsu 214023 ChinaDepartment of Laboratory MedicineThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's HospitalWuxi Medical CenterNanjing Medical UniversityWuxi Jiangsu 214023 ChinaDepartment of Laboratory MedicineThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's HospitalWuxi Medical CenterNanjing Medical UniversityWuxi Jiangsu 214023 ChinaDepartment of Laboratory MedicineThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's HospitalWuxi Medical CenterNanjing Medical UniversityWuxi Jiangsu 214023 ChinaDepartment of Laboratory MedicineThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's HospitalWuxi Medical CenterNanjing Medical UniversityWuxi Jiangsu 214023 ChinaDepartment of Radiology The Affiliated Wuxi People's Hospital of Nanjing Medical University Wuxi Jiangsu 214023 ChinaDepartment of Laboratory MedicineThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's HospitalWuxi Medical CenterNanjing Medical UniversityWuxi Jiangsu 214023 ChinaDepartment of Laboratory MedicineThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's HospitalWuxi Medical CenterNanjing Medical UniversityWuxi Jiangsu 214023 ChinaDepartment of Laboratory MedicineThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's HospitalWuxi Medical CenterNanjing Medical UniversityWuxi Jiangsu 214023 ChinaDepartment of Laboratory MedicineThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's HospitalWuxi Medical CenterNanjing Medical UniversityWuxi Jiangsu 214023 ChinaDepartment of Laboratory MedicineThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's HospitalWuxi Medical CenterNanjing Medical UniversityWuxi Jiangsu 214023 ChinaDepartment of Neurosurgery The Affiliated Wuxi People's Hospital of Nanjing Medical University Wuxi Jiangsu 214023 ChinaWuxi Medical CenterNanjing Medical UniversityWuxi Jiangsu 214023 ChinaDepartment of Laboratory MedicineThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's HospitalWuxi Medical CenterNanjing Medical UniversityWuxi Jiangsu 214023 ChinaAbstract Acetylation is critically required for p53 activation, though it remains poorly understood how p53 acetylation is regulated in glioblastoma (GBM). This study reveals that p53 acetylation is a favorable prognostic marker for GBM, regardless of p53 status, and that Smad1, a key negative regulator of p53 acetylation, is involved in this process. Smad1 forms a complex with p53 and p300, inhibiting p300's interaction with p53 and leading to reduced p53 acetylation and increased Smad1 acetylation in GBM. This results in enhanced tumor growth and resistance to chemotherapy, particularly in tumors with missense mutant p53. Acetylation of K373 is found to be essential for Smad1's oncogenic function but does not confer chemoresistance in the absence of p53. Through molecular docking, it is discovered that Smad1 and p53 both interact with the acetyltransferase domain of p300, but at different amino acid sites. Disturbing the interface of Smad1 through amino acid mutations abolishes the Smad1‐p300 complex and promotes p53 acetylation. Therefore, a small molecule is identified through virtual screening that specifically disrupts the Smad1‐p300 interaction, offering a promising strategy for inhibiting GBM and increasing chemosensitivity by inhibiting Smad1 acetylation and restoring p53 acetylation.https://doi.org/10.1002/advs.202402258glioblastomap300p53Smad1 |
| spellingShingle | Lingli Gong Daxing Xu Kaixiang Ni Jie Li Wei Mao Bo Zhang Zhening Pu Xiangming Fang Ying Yin Li Ji Jingjing Wang Yaling Hu Jiao Meng Rui Zhang Jiantong Jiao Jian Zou Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53 Advanced Science glioblastoma p300 p53 Smad1 |
| title | Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53 |
| title_full | Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53 |
| title_fullStr | Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53 |
| title_full_unstemmed | Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53 |
| title_short | Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53 |
| title_sort | smad1 promotes tumorigenicity and chemoresistance of glioblastoma by sequestering p300 from p53 |
| topic | glioblastoma p300 p53 Smad1 |
| url | https://doi.org/10.1002/advs.202402258 |
| work_keys_str_mv | AT lingligong smad1promotestumorigenicityandchemoresistanceofglioblastomabysequesteringp300fromp53 AT daxingxu smad1promotestumorigenicityandchemoresistanceofglioblastomabysequesteringp300fromp53 AT kaixiangni smad1promotestumorigenicityandchemoresistanceofglioblastomabysequesteringp300fromp53 AT jieli smad1promotestumorigenicityandchemoresistanceofglioblastomabysequesteringp300fromp53 AT weimao smad1promotestumorigenicityandchemoresistanceofglioblastomabysequesteringp300fromp53 AT bozhang smad1promotestumorigenicityandchemoresistanceofglioblastomabysequesteringp300fromp53 AT zheningpu smad1promotestumorigenicityandchemoresistanceofglioblastomabysequesteringp300fromp53 AT xiangmingfang smad1promotestumorigenicityandchemoresistanceofglioblastomabysequesteringp300fromp53 AT yingyin smad1promotestumorigenicityandchemoresistanceofglioblastomabysequesteringp300fromp53 AT liji smad1promotestumorigenicityandchemoresistanceofglioblastomabysequesteringp300fromp53 AT jingjingwang smad1promotestumorigenicityandchemoresistanceofglioblastomabysequesteringp300fromp53 AT yalinghu smad1promotestumorigenicityandchemoresistanceofglioblastomabysequesteringp300fromp53 AT jiaomeng smad1promotestumorigenicityandchemoresistanceofglioblastomabysequesteringp300fromp53 AT ruizhang smad1promotestumorigenicityandchemoresistanceofglioblastomabysequesteringp300fromp53 AT jiantongjiao smad1promotestumorigenicityandchemoresistanceofglioblastomabysequesteringp300fromp53 AT jianzou smad1promotestumorigenicityandchemoresistanceofglioblastomabysequesteringp300fromp53 |